Nervous system conditions and treatments

(189) Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among US Employees

(190) Do efficacy results obtained from randomised controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?

(191) Healthcare resource use (HRU) of patients with active relapsing multiple sclerosis (RMS) using data linkage between a phase IV study and the France's national health data system.

(192) Impact of the disability status of patients with multiple sclerosis on healthcare resource utilization and the ability to work: An analysis of the MSDS-AOK PLUS Linked Database

(193) Inflammatory Bowel Disease among Patients with Multiple Sclerosis and matched Controls: Findings from a Retrospective Cohort Study Utilizing a US Electronic Health Record Database

(195) Systematic emulation trials to evaluate the real-world effectiveness of multiple sclerosis treatments

(197) The Risk of Hypokalemia in Patients Treated with Levetiracetam: A Comparative Cohort Study

(210) Adjunctive treatments for depression: Delineating real-world treatment patterns

(211) Agomelatine and Inverse Risk of Hypertension, Diabetes and Hyperlipidemia: A Nationwide Active-comparator Study

(212) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of methylphenidate and potential signal for obsessive-compulsive disorders

(213) An Assessment of Use and Emerging Safety of Esketamine Nasal Spray in the U.S., 2019-2023

(214) Characteristics and drug utilization patterns of patients with migraine initiating erenumab in Nordic countries

(215) Concurrent Use of Prescription Benzodiazepines and Cannabis in Prevalent Medical Cannabis Users with Mental Health Conditions: A Cross-Sectional Survey

(216) Deprescribing of antidepressants: Development of indicators of high-risk and overprescribing using the RAND/UCLA Appropriateness Method

(217) Effectiveness of low-dose amitriptyline and mirtazapine in insomnia disorder: a randomised, double-blind, placebo-controlled trial in general practice (the DREAMING study)

(219) Identification of migraine in electronic healthcare data sources: a headache for pharmacoepidemiologists – a systematic literature review

(220) Impact of deregulation of the Brazilian National Controlled Products Management System on antidepressants’ sales data

(221) Incidence of moderate and profound hyponatremia during treatment with selective serotonin reuptake inhibitors (SSRIs) – evidence from the Stockholm Sodium Cohort (SSC).

(222) Medically-attended cannabis-related disorders among U.S. Medicare beneficiaries, 2017–2022

(223) Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes

(224) Patient characteristics associated with new community prescription of benzodiazepine and z-drug hypnotics after critical illness in the UK, a retrospective cohort study.

(225) Peyronie´s disease and risk of depression. A nationwide 25-year cohort study

(226) Prevalence and sociodemographic characteristics of people with prescription stimulant use disorder: results from the National Survey on Drug Use and Health, 2015-2019

(227) Risk assessment of decreased platelet count in patients prescribed antidepressants using the MID-NET in Japan

(228) Trends of Triptans Use in Hungary

(299) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of paliperidone, risperidone, and low-energy fracture

(300) Antipsychotics in treatment of adolescents with schizophrenia in China

(301) Anxiety Disorders Diagnosed in Outpatient Encounters Among Commercially Insured US Adults

(303) Benzodiazepine receptor agonists and increased risk of sudden sensorineural hearing loss

(306) Development of matching procedures to identify comparators for real-world comparative evaluations of antipsychotics

(307) Efficacy and safety of riluzole in the treatment of Amyotrophic Lateral Sclerosis, a population based study in Italy

(309) Examining the impact of benzodiazepine formulary restrictions on benzodiazepine-related harms in a Medicaid population, 2004-2016

(310) Fatal intoxications with zopiclone and alprazolam in Sweden during 2012-2020 – a register-based study

(311) Generalized anxiety disorder: Epidemiology, burden, and comorbid depression.

(312) Identifying Longitudinal Medication Adherence Patterns of Antipsychotic Treatments; A Real-World Cohort Study in Catalonia, Spain.

(313) Influence of unemployment on antidepressant sales in drugstores in Brazil: time series analysis, 2014-2021

(314) Mapping the Epidemiological burden of active and lifetime epilepsy in Asian Countries: A Systematic review and Meta-analysis

(316) Potential Association of Syndrome of Inappropriate Antidiuretic Hormone Secretion with Olanzapine Use

(317) Psychotropic medicine use in the German National Cohort (NAKO) baseline

(318) Safety and efficacy of second-generation antipsychotics in Autism Spectrum Disorder: a systematic review and network meta-analysis

(319) The risk of myocarditis, cardiomyopathy and cutaneous vasculitis associated with quetiapine in patients with schizophrenia and bipolar disorder.

(320) Therapeutic strategies after discontinuation of valproate in clinical practice in women with bipolar disorder: a cohort study in the United Kingdom and France databases

(321) Therapeutic strategies after discontinuation of valproate in clinical practice in women with epilepsy: a cohort study in the United Kingdom and France databases

(322) Trends in gabapentinoid prescribing: a nationwide Danish drug utilization study

(323) Trends In Psychotropic Medication Utilisation in Community Pharmacies In Chile Between 2018 - 2022

(324) Utilization of Antiparkinsonian Medication in Romania over 25 years

(325) Utilization of Psychotropic Medications Among Patients Diagnosed with Glioma: A Multinational Drug Utilisation Study